NASDAQ:ACET Adicet Bio Q3 2025 Earnings Report $8.99 +0.25 (+2.86%) As of 01:37 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Adicet Bio EPS ResultsActual EPS-$4.64Consensus EPS -$4.16Beat/MissMissed by -$0.48One Year Ago EPSN/AAdicet Bio Revenue ResultsActual RevenueN/AExpected Revenue$2.50 millionBeat/MissN/AYoY Revenue GrowthN/AAdicet Bio Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time7:00AM ETUpcoming EarningsAdicet Bio's Q2 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Adicet Bio Earnings HeadlinesQ3 Earnings Estimate for Adicet Bio Issued By HC WainwrightAugust 14, 2026 | americanbankingnews.comAdicet Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 6, 2026 | finance.yahoo.comWhy acquisitions are reshaping the gold mining sector right nowGold major acquisitions have repriced junior miners overnight, with past deals delivering gains from 40% to 1,228.6% for shareholders of companies like G2 Goldfields, Loncor Gold, and Rupert Resources. Analyst Garrett Goggin, CFA, CMT, tracks which small miners hold the grade, cash flow, and assets that attract buyout interest from major producers. One quarter of his tracked portfolio has already been acquired as the gold bull market's M and A phase accelerates.August 18 at 1:00 AM | Golden Portfolio (Ad)Lallemand Biofuels & Distilled Spirits and Braskem Announce Bio-Acetone as a Coproduction Opportunity in Ethanol FacilitiesJuly 28, 2026 | financialpost.comFAdicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth ConferenceJuly 21, 2026 | businesswire.comAcetoxystyrene Monomer (ASM) to Reach USD 92.7 Million by 2032, Driven by Rising Demand for High‑Performance Polystyrene Coatings and Growth of Sustainable Packaging SolutionsJuly 20, 2026 | talkmarkets.comSee More Adicet Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adicet Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adicet Bio and other key companies, straight to your email. Email Address About Adicet BioAdicet Bio (NASDAQ:ACET) (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies. Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies. The company also has a pipeline of next-generation candidates targeting solid tumors and autoimmune indications, each built on its platform’s ability to combine γδ T cell receptors with co-stimulatory and cytokine support elements. Early‐stage clinical studies are under way to evaluate safety, tolerability, and preliminary efficacy in multiple patient populations. Founded in 2016 and headquartered in South San Francisco, California, Adicet Bio maintains operations in both the U.S. and Suzhou, China, where it conducts process development and manufacturing. The company completed its initial public offering in February 2020 and has since advanced its platform through strategic collaborations and internal research programs. Under the leadership of Chief Executive Officer Michelle Dipp, Adicet continues to expand its cell therapy capabilities and to position its allogeneic γδ T cell technology as a potential new standard for scalable, off‐the‐shelf immunotherapies.View Adicet Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Home Depot Analysts See a Path to $375 and BeyondRTX Stock Gets a Radar Lock on a $23B Navy WinA Star Investor Just Trimmed Amazon—Here's What It meansFabrinet’s Sell-Off May Prove It Is One of AI’s Most Misunderstood StocksWendy’s Deal Buzz May Give Fast-Food Investors a New Reason to LookMichael Burry Is Betting Against Palantir Again—Should Investors Care?Uncle Sam’s Chip Trick: How the Government Built a Silicon Moat Upcoming Earnings Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026)Walmart (8/20/2026)Deere & Company (8/20/2026)PDD (8/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
